158 related articles for article (PubMed ID: 19939894)
1. CXCR4 expression in early breast cancer and risk of distant recurrence.
Andre F; Xia W; Conforti R; Wei Y; Boulet T; Tomasic G; Spielmann M; Zoubir M; Berrada N; Arriagada R; Hortobagyi GN; Hung MC; Pusztai L; Delaloge S; Michiels S; Cristofanilli M
Oncologist; 2009 Dec; 14(12):1182-8. PubMed ID: 19939894
[TBL] [Abstract][Full Text] [Related]
2. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
Kim J; Takeuchi H; Lam ST; Turner RR; Wang HJ; Kuo C; Foshag L; Bilchik AJ; Hoon DS
J Clin Oncol; 2005 Apr; 23(12):2744-53. PubMed ID: 15837989
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 membrane expression in node-negative breast cancer.
Blot E; Laberge-Le Couteulx S; Jamali H; Cornic M; Guillemet C; Duval C; Hellot MF; Pille JY; Picquenot JM; Veyret C
Breast J; 2008; 14(3):268-74. PubMed ID: 18373506
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
5. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
6. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
8. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
[TBL] [Abstract][Full Text] [Related]
9. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
11. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
Davidson B; Dong HP; Holth A; Berner A; Risberg B
Breast J; 2008; 14(5):476-82. PubMed ID: 18657145
[TBL] [Abstract][Full Text] [Related]
13. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer.
Schimanski CC; Schwald S; Simiantonaki N; Jayasinghe C; Gönner U; Wilsberg V; Junginger T; Berger MR; Galle PR; Moehler M
Clin Cancer Res; 2005 Mar; 11(5):1743-50. PubMed ID: 15755995
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
Mizell J; Smith M; Li BD; Ampil F; Chu QD
Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
[TBL] [Abstract][Full Text] [Related]
15. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
16. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha.
Shim H; Lau SK; Devi S; Yoon Y; Cho HT; Liang Z
Biochem Biophys Res Commun; 2006 Jul; 346(1):252-8. PubMed ID: 16756955
[TBL] [Abstract][Full Text] [Related]
17. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.
Parker BS; Ciocca DR; Bidwell BN; Gago FE; Fanelli MA; George J; Slavin JL; Möller A; Steel R; Pouliot N; Eckhardt B; Henderson MA; Anderson RL
J Pathol; 2008 Feb; 214(3):337-46. PubMed ID: 17985332
[TBL] [Abstract][Full Text] [Related]
18. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
19. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
20. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
Kang H; Mansel RE; Jiang WG
Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
